Dataset:32986807 Search Result
Clinical information
Clinical and Biological Variables Before and After Remdesivir and Convalescent Plasma Treatment
Variables	Baseline, 12 April	Remdesivir, d0 27 May	Remdesivir, d5 31 May	CP, d0 12 June	CP, d10 22 June	CP, d16 28 June	CP, d30 13 July	CP, d80 1 September
Oxygen	Room air	3 L/min	1.5 L/min	1 L/min	Room air	Room air	Room air	Room air
Saturation, %	93	94	98	94	95	95	96	96
Temperature max., °C	38.5	38.9	37.1	38.8	36.5	37.1	36.9	37.8
C-reactive protein, mg/L	14	137	38	77	1	1	1	2
Platelets, g/L	92	86	161	88	144	140	167	131
Leukocytes, g/L	0.810	3.04	2.44	4.7	3.98	4.5	2.94	3.31
Lymphocytes, g/L	0.1	0.06	0.17	0.13	0.32	0.34	0.28	0.37
Date(s) of sampling	12 April, 24 April, 27 April	15 May, 27 May	31 May	9 June	16 June	28 June	13 July	1 September
Nature of sample	Nasop/Nasop/ bronchoalveolar lavage	Nasop	Nasop	Nasop	Nasop	Nasop	Nasop	Nasop
Reverse-transcription polymerase chain reaction result (method)	+(Cep)/+(Pas)	+(Cep)/+(Pas)	+(Cep)	+(Pas)	+(Pas)	+(Pas)	−(Pas)	−(Pas)
Cycle threshold	NA/23	NA/21	NA	21	25	28	NA	NA
Blood viremia (plasma EDTA)	NA	May 27	NA	9 June, 12 June	16 June, 22 June	22 June	13 July	1 September
Log10 copies/mL		3.88		3.94/3.84	Not detected	Not detected	Not detected	Not detected
Anti–severe acute respiratory syndrome coronavirus 2 antibodiesa (optical density index ratio)	NA	…	NA	NA	+5.97	NA	NA	+ 0.92
Remdesivir (d0 = 27 May d5= 31 May) and CP (d0 = 12 June d10 = 22 June, d16 = 28 June, d30 13 July and d80 = 1 September).
Abbreviations: Cep, Cepheid; CP, convalescent plasma; NA, not available; Nasop, nasopharynx, Pas: Pasteur.
aImmunochemiluminescence Roche Cobas 6000 (threshold 0.9–1.10).